NASDAQ: TRML
Tourmaline Bio Inc Stock

$16.26-0.59 (-3.5%)
Updated Apr 29, 2025
TRML Price
$16.26
Fair Value Price
$1.19
Market Cap
$417.52M
52 Week Low
$11.56
52 Week High
$29.79
P/E
-5.62x
P/B
1.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$73.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$77M
Beta
1.22
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

TRML Overview

Talaris Therapeutics Incorporated is a late-clinical stage cell therapy company in the U.S. The company is developing a allogeneic, hematopoietic stem cell transplantation method which, if it succeeds, will transform the standard of care for solid organ transplantation and severe autoimmune diseases, as well as for severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, in a Phase II trial for living donor kidney transplant patients. Talaris was founded in 1988 and is headquartered in Louisville, KY.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TRML's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TRML
Ranked
#361 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TRML news, forecast changes, insider trades & much more!

TRML News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRML scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRML ($16.26) is overvalued by 1,261.55% relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TRML ($16.26) is not significantly undervalued (1,261.55%) relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TRML is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRML due diligence checks available for Premium users.

Valuation

TRML fair value

Fair Value of TRML stock based on Discounted Cash Flow (DCF)

Price
$16.26
Fair Value
$1.19
Overvalued by
1,261.97%
TRML ($16.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRML ($16.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRML is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TRML price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-5.62x
Industry
-158.75x
Market
29.19x

TRML price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.39x
Industry
4.37x
TRML is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TRML's financial health

Profit margin

Revenue
$0.0
Net Income
-$22.2M
Profit Margin
0%
TRML's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$309.0M
Liabilities
$8.9M
Debt to equity
0.03
TRML's short-term assets ($268.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRML's short-term assets ($268.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRML's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRML's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$20.9M
Investing
$16.4M
Financing
-$3.0k
TRML's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TRML vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TRMLD$417.52M-3.53%-5.62x1.39x
OMERD$418.64M-0.83%-2.67x-2.29x
CELCF$424.56M+1.17%-3.96x3.67x
DNAD$428.29M-7.98%-0.70x0.60x
ERASC$405.07M+2.14%-2.07x0.96x

Tourmaline Bio Stock FAQ

What is Tourmaline Bio's quote symbol?

(NASDAQ: TRML) Tourmaline Bio trades on the NASDAQ under the ticker symbol TRML. Tourmaline Bio stock quotes can also be displayed as NASDAQ: TRML.

If you're new to stock investing, here's how to buy Tourmaline Bio stock.

What is the 52 week high and low for Tourmaline Bio (NASDAQ: TRML)?

(NASDAQ: TRML) Tourmaline Bio's 52-week high was $29.79, and its 52-week low was $11.56. It is currently -45.43% from its 52-week high and 40.61% from its 52-week low.

How much is Tourmaline Bio stock worth today?

(NASDAQ: TRML) Tourmaline Bio currently has 25,685,429 outstanding shares. With Tourmaline Bio stock trading at $16.26 per share, the total value of Tourmaline Bio stock (market capitalization) is $417.52M.

Tourmaline Bio stock was originally listed at a price of $162.50 in May 7, 2021. If you had invested in Tourmaline Bio stock at $162.50, your return over the last 3 years would have been -90%, for an annualized return of -53.58% (not including any dividends or dividend reinvestments).

How much is Tourmaline Bio's stock price per share?

(NASDAQ: TRML) Tourmaline Bio stock price per share is $16.26 today (as of Apr 29, 2025).

What is Tourmaline Bio's Market Cap?

(NASDAQ: TRML) Tourmaline Bio's market cap is $417.52M, as of Apr 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tourmaline Bio's market cap is calculated by multiplying TRML's current stock price of $16.26 by TRML's total outstanding shares of 25,685,429.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.